Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980024 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2700937 | 0.83 | EGFR (0.59) | EGFRERBB2ERBB4ABL1INSR | |
| SCHEMBL4720051 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3320212 | 0.82 | EGFR (0.69) | EGFRERBB2GAKERBB4HDAC1 | |
| SCHEMBL141514 | 0.81 | EGFR (0.73) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL9973594 | 0.81 | EGFR (0.58) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL29693649 | 0.81 | EGFR (0.73) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2699753 | 0.81 | EGFR (0.58) | EGFRERBB2GAKERBB4ABL1 | |
| Hydrochloric Acid SCHEMBL215037 | 0.80 | EGFR (0.72) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3014295 | 0.79 | EGFR (0.63) | EGFRERBB2GAKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| EP-2448409-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | Newgen Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002523-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | KANIONUSA INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | EGFR 718/4885ERBB2 446/4885GAK 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.